PTPRB — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL467900	1.00	20/20
SCHEMBL467957	1.00	20/20
SCHEMBL467958	1.00	20/20
SCHEMBL468026	1.00	20/20
SCHEMBL468028	1.00	20/20
SCHEMBL468035	1.00	20/20
SCHEMBL468045	1.00	20/20
SCHEMBL468047	1.00	20/20
SCHEMBL468056	1.00	20/20
SCHEMBL468057	1.00	20/20
SCHEMBL468065	1.00	20/20
SCHEMBL468066	1.00	20/20
SCHEMBL468067	1.00	20/20
SCHEMBL468069	1.00	20/20
SCHEMBL468071	1.00	20/20
SCHEMBL468083	1.00	20/20
SCHEMBL468093	1.00	20/20
SCHEMBL468094	1.00	20/20
SCHEMBL468103	1.00	20/20
SCHEMBL468105	1.00	20/20

Clinical trials — most relevant to PTPRB by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy	PHASE4	COMPLETED
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis	PHASE4	COMPLETED
co Ihibtory Receptor in Preeclampsia	PHASE4	UNKNOWN
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia	PHASE3	RECRUITING
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF	PHASE3	COMPLETED
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation	PHASE2	UNKNOWN
Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer	PHASE2	UNKNOWN
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)	PHASE1/PHASE2	COMPLETED
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Cyclosporine For The Treatment Of COVID-19(+)	PHASE2	COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	PHASE1	COMPLETED
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC)	nan	UNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies	nan	UNKNOWN
Using of Costimulatory and co Inhibatory Immune Checkpoints as Diagnostic and Prognostic in Breast Cancer	nan	UNKNOWN
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes	nan	RECRUITING
Longitudinal Prognosis of Lymphoproliferative Manifestations in Primary Immunodeficiencies	nan	NOT_YET_RECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Evaluation of the Level of Expression of CD45RC on T Lymphocytes as a Predictive Biomarker of Acute Rejection After Renal Transplantation	nan	RECRUITING
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PTPRB binder may also engage these)

Protein	Name	Similarity
B2RU80	—	1.000	B2RU80 →
O88488	—	0.982	O88488 →
P35992	—	0.981	P35992 →
A2AED3	—	0.981	A2AED3 →
PTPRM	Receptor-type tyrosine-protein phosphatase mu	0.979	landscape →
Q9UMZ3	—	0.977	Q9UMZ3 →
Q5VTL7	—	0.977	Q5VTL7 →
P0C5E4	—	0.977	P0C5E4 →
Q2EY13	—	0.977	Q2EY13 →
Q02858	—	0.977	Q02858 →
Q99M80	—	0.976	Q99M80 →
P28828	—	0.975	P28828 →
F1NWE3	—	0.975	F1NWE3 →
Q8BYI9	—	0.975	Q8BYI9 →
P54757	—	0.975	P54757 →
O42422	—	0.975	O42422 →
Q2VWP9	—	0.974	Q2VWP9 →
Q2EY15	—	0.974	Q2EY15 →
TEK	Angiopoietin-1 receptor	0.974	landscape →
P35822	—	0.974	P35822 →
P54755	—	0.974	P54755 →
Q6X862	—	0.974	Q6X862 →
Q06807	—	0.974	Q06807 →
EPHA6	Ephrin type-A receptor 6	0.973	landscape →
EPHA5	Ephrin type-A receptor 5	0.973	landscape →
Q0V8T5	—	0.973	Q0V8T5 →
Q2VWP7	—	0.973	Q2VWP7 →
Q91740	—	0.973	Q91740 →
P16621	—	0.973	P16621 →
P53767	—	0.973	P53767 →